Insulin resistance may contribute to chemotherapy resistance in individuals with colon cancer; as such, two colon cancer cell lines were used to determine whether the expression of IRS‐1 would affect the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment (Figure 1A). The gene discussed is IRS1; the disease is malignant colon neoplasm.